DBV TECHNOLOGIE/S (NASDAQ:DBVT) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Several other brokerages also recently commented on DBVT. Zacks Investment Research raised shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Tuesday, July 17th. ValuEngine raised shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Finally, Morgan Stanley raised their price target on shares of DBV TECHNOLOGIE/S from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, July 13th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $39.75.

Shares of NASDAQ:DBVT opened at $19.00 on Tuesday. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 0.01. DBV TECHNOLOGIE/S has a one year low of $16.65 and a one year high of $50.57. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -5.64 and a beta of 0.92.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of DBV TECHNOLOGIE/S by 20.2% during the 4th quarter. Geode Capital Management LLC now owns 20,833 shares of the company’s stock worth $512,000 after acquiring an additional 3,499 shares during the last quarter. Bailard Inc. purchased a new position in DBV TECHNOLOGIE/S in the 1st quarter worth $1,084,000. Alps Advisors Inc. raised its position in DBV TECHNOLOGIE/S by 21.0% in the 1st quarter. Alps Advisors Inc. now owns 67,004 shares of the company’s stock worth $1,546,000 after purchasing an additional 11,646 shares during the period. Millennium Management LLC raised its position in DBV TECHNOLOGIE/S by 842.6% in the 1st quarter. Millennium Management LLC now owns 133,256 shares of the company’s stock worth $3,074,000 after purchasing an additional 119,119 shares during the period. Finally, First Midwest Bank Trust Division raised its position in DBV TECHNOLOGIE/S by 36.7% in the 2nd quarter. First Midwest Bank Trust Division now owns 136,986 shares of the company’s stock worth $2,642,000 after purchasing an additional 36,798 shares during the period. 45.58% of the stock is owned by institutional investors.

About DBV TECHNOLOGIE/S

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

See Also: Find a Trading Strategy That Works

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.